Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)

Clinical trials for orphan diseases are critical for developing effective therapies. One such condition, fibrodysplasia ossificans progressiva (FOP; MIM#135100), is characterized by progressive heterotopic ossification (HO) that leads to severe disability. Individuals with FOP are extremely sensitive to even minor traumatic events. There has been substantial recent interest in clinical trials for novel and urgently‐needed treatments for FOP. The International Clinical Council on FOP (ICC) was established in 2016 to provide consolidated and coordinated advice on the best practices for clinical care and clinical research for individuals who suffer from FOP. The Clinical Trials Committee of the ICC developed a focused list of key considerations that encompass the specific and unique needs of the FOP community – considerations that are endorsed by the entire ICC. These considerations complement established protocols for developing and executing robust clinical trials by providing a foundation for helping to ensure the safety of subjects with FOP in clinical research trials.

[1]  E. Hsiao,et al.  Fibrodysplasia ossificans progressiva: a current review of imaging findings , 2018, Skeletal Radiology.

[2]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..

[3]  J. Kostis,et al.  Diagnostic Medical Imaging in Pediatric Patients and Subsequent Cancer Risk. , 2017, Academic radiology.

[4]  Adam J Pawson,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes , 2017, British journal of pharmacology.

[5]  E. Hsiao,et al.  Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva. , 2017, Bone.

[6]  G. Pals,et al.  [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva. , 2017, Bone.

[7]  R. Pignolo,et al.  A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). , 2017, Bone.

[8]  G. Pals,et al.  Flare‐Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]‐NaF PET/CT Study and a Systematic Review , 2017, JBMR plus.

[9]  P. Landais,et al.  Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases , 2017, Orphanet Journal of Rare Diseases.

[10]  R. Pignolo,et al.  Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  David M. Rocke,et al.  The Natural History of Flare‐Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  P. Laterre,et al.  Strengths and limitations of industry vs. academic randomized controlled trials. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  C. Chambers,et al.  Interventions for Individuals With High Levels of Needle Fear , 2015, The Clinical journal of pain.

[14]  F. Kaplan,et al.  General Anesthesia for Dental Procedures in Patients with Fibrodysplasia Ossificans Progressiva: A Review of 42 Cases in 30 Patients , 2014, Anesthesia and analgesia.

[15]  A. Martini,et al.  Impact of the European paediatric legislation in paediatric rheumatology: past, present and future , 2013, Annals of the rheumatic diseases.

[16]  David M. Rocke,et al.  Neurological symptoms in individuals with fibrodysplasia ossificans progressiva , 2012, Journal of Neurology.

[17]  R. Goldsby,et al.  CNS demyelination in fibrodysplasia ossificans progressiva , 2012, Journal of Neurology.

[18]  M. Bullinger,et al.  Determinants of decision-making and patient participation in paediatric clinical trials: A literature review , 2012 .

[19]  David M. Rocke,et al.  Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. , 2010, The Journal of bone and joint surgery. American volume.

[20]  S. Mundlos,et al.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 , 2009, Human mutation.

[21]  David M. Rocke,et al.  Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva , 2005, Pediatrics.

[22]  P. Billings,et al.  Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway , 2005 .

[23]  C. R. Reed,et al.  Recent trends and controversies in industry-sponsored clinical trials. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[24]  F. Kaplan,et al.  THE MEDICAL MANAGEMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: CURRENT TREATMENT CONSIDERATIONS , 2011 .

[25]  In Ho Choi,et al.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva , 2006, Nature Genetics.